Most studies (mentioned in Section 7, Section 8 and Section 9 and Table 2, Table 3 and Table 4) support the findings that GnRH agonist co-treatment protects from gonadotoxicity and preserves fertility in chemotherapy-treated pre-menopausal women with breast cancer and hematological malignancy. Here, GNRH1 is linked to breast carcinoma.